Regional footprint Egis operates across 18 countries with a network of subsidiaries and representative offices, selling products under Egis brands beyond Hungary and reaching 100 countries through partners, signaling opportunities to expand in Central and Eastern Europe and neighboring markets.

Biosimilar momentum Since introducing the first EU-approved biosimilar monoclonal antibody and launching three more since, Egis has demonstrated capability in high-value biologics, suggesting potential collaboration or contract manufacturing for biosimilars and biologic product lines.

R&D heavy With annual R&D investment of over EUR 45 million and ongoing modernization of manufacturing and early-stage development, there are opportunities to position Egis as a partner for branded generics and innovative formulations across cardiovascular, CNS, diabetology, and skin/wound care therapies.

Attractive employer Recent recognitions as a top employer in Hungary and in Randstad life sciences branding indicate strong talent and organizational stability, which can facilitate joint ventures, partnerships, and regional commercialization efforts requiring skilled teams.

Expansion capabilities Significant investments at the Körmend and Budapest sites, including new galenic and oncology-focused manufacturing capacities, imply readiness to scale manufacturing for long-term supply contracts, line extensions, or CDMO collaborations in high-growth therapeutic areas.